Cara Fraley, M.S.

Cara Fraley is a research scientist I in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard under the direction of Colin Garvie. She is part of a team that carries out drug discovery campaigns based on genetic and phenotypic targets identified by Broad’s academic labs and screening platforms. 

Fraley joined the Broad Institute in August 2012 as a senior research associate and transitioned into her current post in January 2018. She previously worked as a senior associate scientist for Biogen Idec/Syntonix Pharmaceuticals performing assay development for several successful programs including the long lasting hemophilia drugs Alprolix and Eloctate. Prior to Biogen, Fraley worked at the Faculte de Pharmacie in Illkirch, France, where she studied GPCRs and spent her free time sampling Alsatian wines and cheeses. Fraley began her career at a small startup, Mosaic Technologies, performing assay development on a technology that was later sold to Exact Sciences and evolved into their Cologuard diagnostic test for colon cancer screening.

Fraley has an M.S. in biochemistry from Boston College and a B.S. in chemistry from Seton Hall University.  

Contact Cara Fraley via email at cfraley@broadinstitute.org.